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Background. This study investigated the association between betel nut chewing and subclinical ischemic heart disease (IHD) in
Taiwanese type 2 diabetic patients. Methods. A total of 394 male patients aging ≥45 years and without previous heart disease
were studied. Among them 349 had no habit of chewing betel nut and 45 possessed the habit for ≥5 years. Subclinical IHD
was diagnosed by a Minnesota-coded resting electrocardiogram and was present in 71 cases. Statistical analyses were performed
considering confounding eﬀects of age, diabetic duration, smoking, body mass index, blood pressure, dyslipidemia, and metabolic
control status. Results. Betel nut chewers were younger and had higher prevalence of smoking (86.7% versus 60.5%), higher body
mass index, poorer glycemic control, and higher prevalence of subclinical IHD (28.9% versus 16.6%). Patients with subclinical
IHD were older and had higher prevalence of betel nut chewing (18.0% versus 9.9%). The multivariate-adjusted odds ratio for
subclinical IHD for chewers versus nonchewers was 4.640 (1.958–10.999). The adjusted odds ratios in younger or older patients
divided by the median age of 63 years were similar: 4.724 (1.346–16.581) and 4.666 (1.278–17.028), respectively. Conclusions.B e t e l
nut chewing is signiﬁcantly associated with increased risk of subclinical IHD.
1.Introduction
Areca nut is the seed of the palm tree Areca catechu,w h i c h
is the fourth most commonly used psychoactive substance,
after caﬀeine, nicotine, and alcohol [1]. Because areca nut
is always consumed with the leaf of Piper betle, chewing of
areca nut has always been referred to as “betel nut chewing”
intheEnglishliterature[2].Thereisanestimated600million
peoplechewingbetelnutworldwide[3].Itisacommonhabit
and is a means of social interaction in Asia, particularly the
South Paciﬁc islands, Southeast Asia, Papua New Guinea,
Bangladesh, Pakistan, and India [1–4]. Chewing of betel nut
was forbidden in Taiwan during the Japanese reign more
than 60 years ago [4] .B u tt h i sh a b i th a sb e c o m ep o p u l a r
in Taiwan during the past two to three decades, and it has
been estimated that about 2.4 millions, or 11.4%, of the
total population are chewing betel nut [5]. The chewing
population in Taiwan keeps on increasing, especially in the
male sex of the younger generation [6, 7]. In Taiwan, unripe
areca nut is commonly chewed with a mixture of lime and
the leaf or ﬂower of the Piper betle, but without tobacco [4].
Betel nut chewing has been linked to a variety of health
problems including oral lesions of leukoplakia, submucosal
ﬁbrosis, squamous cell carcinoma and periodontal disease
[8, 9], albuminuria in diabetic patients [10], disruption
of gastric mucosal barriers [11], aggravation of asthma
[12], induction of extrapyramidal syndrome [13], milk-
alkali syndrome (in a case report) [14], induction of uterine
cervical dysplasia [15], cancers of the esophagus [16]a n d
liver [17], and low birth weight of babies born to mothers
chewing betel nut [18]. In more recent population-based
studies in Taiwan, betel nut chewing is also associated with
a higher risk of type 2 diabetes mellitus (T2DM) [19],
hypertension[20],andtotalandcerebrovasculardeaths[21].
Studies on the cardiovascular eﬀects of betel nut chewing
are rare. Hemodynamic changes have been observed during
betel nut chewing [7]. However, whether the prolonged
chewing of betel nut could exert an eﬀect on the heart2 Cardiology Research and Practice
has not been previously studied. Therefore, the purpose of
this study was to evaluate whether betel nut chewing could
be associated with the prevalence of subclinical IHD in a
subgroup of patients with T2DM recruited as a long-term
follow-up cohort in Taiwan.
2. Methods
2.1. Study Subjects. The study was approved by an ethics
committee of the Department of Health, Taiwan, and the
subjectsvoluntarilyparticipatedinthestudy.Morethan96%
of the population of Taiwan is covered by a compulsory
National Health Insurance program. A total of 256,036
patients using this health insurance program were assembled
from 1995 to 1998 [22–24]. Baseline data was collected by
questionnaires on the onset symptoms and conﬁrmation of
diabeticdiagnosisfrom93,484patientsoftheoriginalcohort
[22–24]. At random, 4,164 patients were selected from the
main cluster of 93,484 patients and invited to participate in a
health examination. A total of 1,441 patients participated in
thehealthexaminationfromMarch1998toSeptember2002.
After excluding 21 patients with type 1 diabetes mellitus
(T1DM), there were a total of 1420 patients diagnosed as
T2DM. The patients with T2DM did not show a history
of diabetic ketoacidosis at the onset of diabetes and were
being treated with either oral antidiabetic drugs or insulin at
the time of recruitment. For those under insulin treatment,
none received such treatment within one year of diagnosis of
diabetes mellitus.
Patients with T1DM were excluded because of the small
number of cases who might also have diﬀerent pathogenesis
of IHD. Women with T2DM were further excluded because
the habit of betel nut chewing is very uncommon in women
in Taiwan [6, 7, 25]. Taking into account the possible
requirement of prolonged chewing for the manifestations
of clinical outcomes, this study recruited only adult male
patients aging ≥45 years, and chewers must be current
chewers and have retained the habit for ≥5 years at the
time of recruitment. Patients with a clinical history of heart
disease including angina pectoris, myocardial infarction,
congestive heart failure or under treatment for such were
also excluded because of the impossibility to clarify the
correctness of temporality between cause and eﬀects and
because of the potential confounding eﬀect caused by
treatments. As a result, a total of 394 men with T2DM were
included in this study. They were divided into two groups:
one with no habit of chewing betel nut and the other should
have persistently chewed betel nut for more than 5 years at
the time of recruitment.
2.2. Diagnosis of Subclinical Ischemic Heart Disease. Resting
electrocardiogram was performed in each subject, and the
Minnesota codes were used to code the electrocardiograms.
The coder was blind to the history or the biochemical data
of the subjects. Subclinical IHD was deﬁned by Minnesota
codes of coronary probable (1.1, 1.2, 7.1) and coronary
possible (1.3, 4.1–4.3, 5.1–5.3) [26].
2.3. Measurements of Blood Biochemistry and Other Covari-
ates. Blood sampleswerecollectedin the earlymorning after
fasting for at least 12 hours. Fasting plasma glucose (FPG),
serum total cholesterol (TC), and triglyceride (TG) were
measured by an automatic biochemistry analyzer (Cobas
Mira S, Roche Diagnostica, Basel, Switzerland) with reagents
obtained from Randox Laboratories Ltd. (Antrium, UK)
[27].
The patients’ age, duration of diabetes, body mass index
(BMI), smoking status, and systolic (SBP) and diastolic
blood pressure (DBP) were recorded or measured. Duration
of diabetes was deﬁned as the time period in years between
the time being recruited into the study and the time diabetes
was diagnosed. Blood pressure was measured on the right
arm after 20 minutes rest in a sitting position with a
mercury sphygmomanometer by the auscultatory method.
Body height (in centimeters) was measured by having the
subjects stand with their heals, buttocks, and heads against
a wall. A ﬂat object was placed on top of the subjects’ head,
and their height was marked on a tape measure aﬃxed to
the wall. Body weight was measured in kilograms with a
standard portable scale. Body height and body weight were
measured with the patient wearing light clothes and without
socks and shoes. BMI was calculated as body weight in
kilogramsdividedbythesquareofthebodyheightinmeters.
Hypertension was deﬁned by a positive history with the use
of antihypertensive agents or by SBP ≥ 140mmHg and/or
DBP ≥ 90mmHg. Dyslipidemia was diagnosed by the use of
lipid-lowering agents and/or a TC level ≥ 200mg/dL and/or
TG ≥ 150mg/dL.
2.4. Statistical Analyses. Data were expressed as mean (SD)
or percentage. A P<. 05 was considered statistically
signiﬁcant, while .05 <P<. 1 was borderline signiﬁcant. Age
was divided into two groups by the median and the preva-
lences of subclinical IHD between chewers and nonchewers
were compared by Chi-square test in the respective age
groups. The baseline characteristics between chewers and
nonchewers and between patients with subclinical IHD and
those without subclinical IHD were compared by Student’s
t-test for continuous variables and by Chi-square test for
categorical variables. Logistic regression models estimating
the odds ratios for subclinical IHD were created for all
patients and for patients in the respective two age groups
divided by the median of age. These regression models
were generated in the following 3 ways: (1) unadjusted; (2)
adjusted for variables found to be diﬀerent between chewers
and non-chewers, or between patients with and without
subclinical IHD with P values < .1; (3) adjusted for all
potential covariates (i.e., age, diabetic duration, body mass
index, smoking, hypertension, dyslipidemia, FPG, SBP, DBP,
TC, and TG).
3. Results
Figure 1 shows the prevalences of subclinical IHD in chewers
and non-chewers in the respective age groups divided by the
median of 63 years old. The prevalences of subclinical IHD
diﬀered signiﬁcantly between chewers and non-chewers in
either the younger or the older age groups (P<. 05).Cardiology Research and Practice 3
Table 1: Comparisons between patients chewing and not chewing betel nut and having and not having subclinical ischemic heart disease
(IHD).
Betel nut chewing Subclinical IHD
No Yes No Yes
n 349 45 323 71
Age, years 63.9 (9.3) 56.3 (8.6)∗∗ 62.0 (9.4) 67.6 (9.1)∗∗
Diabetic duration, years 10.4 (7.6) 10.3 (8.8) 10.4 (7.6) 10.7 (8.5)
Body mass index, kg/m2 24.5 (3.0) 25.9 (3.7)∗∗ 24.6 (3.2) 24.8 (2.9)
Smoking, % 60.5 86.7∗∗ 63.2 64.8
Fasting plasma glucose, mg/dL 159.4 (57.3) 178.6 (74.8)∗ 162.2 (56.5) 159.1 (72.9)
Hypertension, % 52.4 60.0 52.3 57.8
Systolic blood pressure, mmHg 132.8 (15.8) 131.9 (16.1) 132.1 (15.4) 135.2 (17.5)
Diastolic blood pressure, mmHg 83.2 (8.8) 84.8 (7.0) 83.4 (8.4) 83.1 (9.6)
Dyslipidemia, % 56.0 68.9 56.5 62.0
Total cholesterol, mg/dL 199.8 (45.9) 196.9 (38.2) 199.1 (45.1) 201.3 (44.9)
Triglyceride, mg/dL 168.7 (193.3) 180.0 (83.1) 168.9 (196.2) 174.9 (114.6)
Ischemic heart disease, % 16.6 28.9∗ ——
Betel nut chewing, % — — 9.9 18.0∗
∗P <. 05; ∗∗P <. 01.
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Figure 1: Prevalence of subclinical ischemic heart disease (IHD)
between betel nut chewers (shaded column) and non-chewers
(black column) by median of age (P<. 05 for each subgroup of
age).
Table 1 compares the baseline characteristics between
chewers and nonchewers and between patients with and
without subclinical IHD. Chewers were signiﬁcantly younger
in age, more prevalent in smoking and subclinical IHD, and
had higher BMI and poorer glycemic control. Patients with
subclinical IHD were signiﬁcantly older and more prevalent
in betel nut chewing.
Table 2 shows the odds ratios for subclinical IHD.
Chewers consistently showed a signiﬁcantly higher risk of
subclinical IHD in either the older or the younger age group
in all of the models.
4. Discussion
The ﬁndings of this study clearly demonstrated a higher risk
of subclinical IHD in T2DM patients without a previous
history of heart disease (Tables 1 and 2; Figure 1). This
association was independent of traditional risk factors, and
could be demonstrated in either the younger or the older
patients (Figure 1; Table 2). To the best of our knowledge,
this was the ﬁrst study demonstrating a link between betel
nut chewing and subclinical IHD. The association was
consistent, and the magnitude of the odds ratios was large.
Although the real pathogenetic mechanism(s) remains
unknown, some of the biological eﬀects associated with the
ingredients of areca nut or the compounds formed during
chewing might explain some of the possibilities. The com-
mon preparations of the betel nut quid in Taiwan consist of
threemajorcomponents:thenutofArecacatechu,quicklime,
andtheleafortheﬂowerofPiperbetle[4].Arecanutcontains
arecoline which has a cholinergic action at the muscarinic
and nicotinic receptors [28]. This cholinergic action on the
central nervous system could possibly produce the cortical
arousal and alertness which is always claimed as one of the
merits experienced by the betel nut chewers. On the other
hand, arecoline might stimulate the hypothalamic-pituitary-
adrenal axis through a centrally mediated corticotrophin-
releasinghormone-dependentmechanisminrats[29].Inthe
presence of lime, arecoline is hydrolyzed to arecaidine, which
lacks the parasympathomimetic eﬀects of arecoline [4]a n d
exerts sympathetic eﬀect by inhibition of γ-aminobutyric
acid (GABA) uptake [30]. However, a later study suggested
that arecaidine may not cross the blood-brain barrier and
the central eﬀects may involve transmitters other than GABA
[31]. The aromatic substances (e.g., eugenol, isoeugenol,
a n dh y d r o x y c h a v i c o l )i nt h eﬂ o w e ro rl e a fo fPiper betle
can stimulate the release of catecholamines from chromaﬃn
cells in vitro [32], and circulating norepinephrine and
epinephrine levels are elevated following betel nut chewing
[33]. However, these sympathomimetic eﬀects of arecoline
might be mediated by central cholinergic mechanisms [34].
Therefore, both areca nut and Piper betle ﬂower may exert
sympathomimetic eﬀects. Whether these sympathomimetic
eﬀects may be responsible for the subclinical IHD observed
in the present study awaits further investigations. Reactive4 Cardiology Research and Practice
Table 2: Odds ratios for subclinical ischemic heart disease comparing chewers versus nonchewers of betel nut.
Odds ratio (95% conﬁdence interval)
<63 years old ≥63 years old All ages
Unadjusted 2.982 (1.087–8.182)∗ 3.267 (1.004–10.629)∗ 2.038 (1.008–4.118)∗
Adjusted for age, BMI,
smoking, and FPG
4.153 (1.280–13.471)∗ 4.183 (1.170–14.955)∗ 4.269 (1.837–9.920)∗∗
Adjusted for all covariates
(age, diabetic duration,
BMI, smoking,
hypertension,
dyslipidemia, FPG, SBP,
DBP, TC, and TG)
4.724 (1.346–16.581)∗ 4.666 (1.278–17.028)∗ 4.640 (1.958–10.999)∗∗
∗P<. 05; ∗∗P <. 01.
oxygen species and N-nitroso compounds can also be
formed in the oral cavity during chewing of betel nut [35,
36]. In vitro studies also demonstrated that betel nut compo-
nents increased the release of inﬂammatory mediators such
as prostanoids, interleukin-6, and tumor necrosis factor-α
[37, 38]. The production of these chemical agents has
always been regarded as the mediators of carcinogenicity and
diabetogenicity associated with betel nut chewing. Whether
they can also be responsible for a hemodynamic or structural
change in the coronary vascular system leading to subclinical
IHD is an issue worthy of further investigation.
Some limitations deserve mentioning. This study was
conducted in the diabetic patients, and it is not known
whether similar eﬀects can be extended to the general pop-
ulation without diabetes. Future studies should be aimed at a
dose-response relationship and taking the duration of betel
nut chewing into consideration. Longitudinal prospective
studies are required to clarify the cause/eﬀect relationship
between betel nut chewing and subclinical IHD.
In conclusions, betel nut chewing in Taiwanese patients
with T2DM is associated with subclinical IHD. While the
chewing of betel nut is decreasing in some countries like
Thailand [39], the prevalence keeps on increasing in Taiwan,
especially in the younger generation. It is urgent for policy
makers to implement programs of health education to the
younger generation to curb the increasing prevalenceof betel
nut chewing and its associated health problems.
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